查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1888752

核酸治療契約製造市場規模、佔有率和趨勢分析報告：按類型、服務、應用、最終用途、地區和細分市場預測（2025-2033 年）

Nucleic Acid Therapeutics Contract Manufacturing Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End Use, By Application, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

核酸治療藥物契約製造市場摘要

2024年全球核酸治療藥物契約製造市場規模估計為98.5億美元，預計到2033年將達到338.4億美元。

預計從 2025 年到 2033 年，該市場將以 15.14% 的複合年成長率成長。生物製藥外包趨勢的日益成長、mRNA 療法和基因療法需求的成長以及製造技術的進步推動了該市場持續成長。

監管支持的加強和政府激勵措施也是推動市場成長的因素。生物製藥公司將營運外包給契約製造製造商的趨勢日益成長，預計將推動全球市場成長。這種外包活動使他們能夠降低營運成本、加快產品上市速度並利用核酸生產方面的專業知識。根據2025年7月發表的報導，82.6%的細胞和基因治療（CGT）公司至少將生物製藥生產外包，這表明對外部契約製造服務的依賴程度已達到歷史最高水準。

此外，mRNA、質體DNA和寡核苷酸療法的複雜性是推動外包活動的主要原因，這些療法需要符合GMP標準的設施、熟練的人員和先進的技術。這導致對契約製造的需求增加，這些製造商需要提供包括製程開發、分析測試和商業化生產在內的綜合服務。此外，外包使製藥公司能夠專注於研發，確保符合監管要求和品質標準。

目錄

第1章調查方法和範圍

第2章執行摘要

3. 核酸治療藥物契約製造市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 科技趨勢
  • 定價模式分析
  • 關稅影響分析
  • 價值鏈分析
    • 供應趨勢
    • 需求趨勢
  • 市場分析工具
    • 波特五力分析
    • PESTEL 分析與 SWOT 分析

第4章 核酸治療藥物契約製造市場：按類型分類的估計和趨勢分析

  • 核酸治療藥物契約製造市場按類型分類：波動分析
  • 核酸治療藥物契約製造市場按類型分類的估計和預測，2021-2033年
  • 基因治療
    • 質體DNA（pDNA）
    • 病毒載體
    • 非病毒基因轉移系統
    • 其他
  • 基於RNA的治療方法
    • 傳訊RNA（mRNA）
    • 小干擾RNA（siRNA）
    • 反義寡核苷酸（ASO）
    • 其他

第5章 核酸治療藥物契約製造市場：按服務類型分類的估計和趨勢分析

  • 核酸治療藥物契約製造市場：按服務類型分類的差異分析
  • 核酸治療藥物契約製造市場按服務類型分類的估計和預測，2021-2033年
  • 製程開發與最佳化
  • GMP生產
  • 分析和品管服務
  • 灌裝/包裝契約製造
  • 監管支持
  • 其他

第6章 核酸治療藥物契約製造市場：按應用分類的估算與趨勢分析

  • 核酸治療藥物契約製造市場：按應用領域分析變化
  • 核酸治療藥物契約製造市場按應用領域分類的估計與預測，2021-2033年
  • 腫瘤學
  • 罕見疾病
  • 遺傳性疾病
  • 感染疾病
  • 其他

第7章 核酸治療藥物契約製造市場：依最終用途分類的估算與趨勢分析

  • 核酸治療藥物契約製造市場：依最終用途分類的差異分析
  • 核酸治療藥物契約製造市場按最終用途分類的估計和預測，2021-2033年
  • 大型生物製藥公司
  • 中型生物製藥公司
  • 中小型生物製藥公司
  • 其他

第8章：核酸治療藥物契約製造市場：區域估計與趨勢分析

  • 區域市場概覽
  • 區域市場佔有率分析（2024 年和 2033 年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 科威特
    • 卡達
    • 阿曼

第9章 競爭情勢

  • 主要參與者的分類
    • 市場領導
    • 新興企業
  • 2024年市場佔有率/評估分析（熱力圖分析）
  • 公司簡介
    • Lonza Group
    • Thermo Fisher Scientific
    • Catalent Inc.
    • WuXi AppTec
    • AGC Biologics
    • Agilent Technologies
    • Ajinomoto Bio-Pharma Services
    • BioSpring GmbH
    • Bachem Holding AG
    • CordenPharma International GmbH
    • Danaher Corporation
    • Eurofins Scientific
    • Avecia（Nitto Denko/Avecia）
    • BioCina Pty Ltd.
    • Kaneka Corporation
Product Code: GVR-4-68040-809-4

Nucleic Acid Therapeutics Contract Manufacturing Market Summary

The global nucleic acid therapeutics contract manufacturing market size was estimated at USD 9.85 billion in 2024 and is projected to reach USD 33.84 billion by 2033, growing at a CAGR of 15.14% from 2025 to 2033. The market is witnessing growth driven by growing biopharmaceutical outsourcing trends, rising demand for mRNA and gene therapies, and technological advancements in manufacturing.

Increasing regulatory support and government incentives are among the other factors driving market growth. In the global market, shifting trends towards outsourcing activities by biopharmaceutical companies to contract manufacturers are expected to drive market growth. This outsourcing activity reduces operational costs, accelerates time-to-market, and utilizes specialized expertise in nucleic acid production. According to an article published in July 2025, 82.6% of cell and gene therapy (CGT) companies outsource at least part of their biologics manufacturing, marking record-high levels of reliance on external contract manufacturing services.

In addition, outsourcing activities is also driven by the high complexity of mRNA, plasmid DNA, and oligonucleotide therapeutics, which require GMP-certified facilities, skilled personnel, and advanced technologies. Thus, contract manufacturers are witnessing an increasing requirement for integrated services, including process development, analytical testing, and commercial-scale manufacturing. In addition, outsourcing enables pharmaceutical firms to concentrate on research and development, ensuring that regulatory compliance and quality standards are met.

Global Nucleic Acid Therapeutics Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global nucleic acid therapeutics contract manufacturing market report based on type, service, application, end use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Gene Therapy
    • Plasmid DNA (pDNA)
    • Viral Vectors
    • Non-viral Gene Delivery Systems
    • Others
  • RNA-based Therapies
    • Messenger RNA (mRNA)
    • Small Interfering RNA (siRNA)
    • Antisense Oligonucleotides (ASO)
    • Other
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Process Development and Optimization
  • GMP Manufacturing
  • Analytical and Quality Control Service
  • Fill-Finish Contract Manufacturing
  • Regulatory Support
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Rare Diseases
  • Genetic Disorders
  • Infectious Diseases
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Large Biopharmaceutical Companies
  • Medium Biopharmaceutical Companies
  • Small Biopharmaceutical Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
    • Qatar
    • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Service
    • 1.2.3. Application
    • 1.2.4. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Botton-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Nucleic Acid Therapeutics Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Demand for Cell and Gene Therapies
      • 3.2.1.2. Increased Outsourcing by Biopharma Companies
      • 3.2.1.3. Technological Advancements in Manufacturing Platforms
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Production Complexity and Cost
      • 3.2.2.2. Limited Skilled Workforce and Technical Expertise
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Value Chain Analysis
    • 3.6.1. Supply Trends
    • 3.6.2. Demand Trends
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Force Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Nucleic Acid Therapeutics Contract Manufacturing Market: Type Estimates & Trend Analysis

  • 4.1. Nucleic Acid Therapeutics Contract Manufacturing Market, By Type: Segment Dashboard
  • 4.2. Nucleic Acid Therapeutics Contract Manufacturing Market, By Type: Movement Analysis
  • 4.3. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
  • 4.4. Gene Therapy
    • 4.4.1. Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Plasmid DNA (pDNA)
      • 4.4.2.1. Plasmid DNA (pDNA) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Viral Vectors
      • 4.4.3.1. Viral Vectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Non-viral Gene Delivery Systems
      • 4.4.4.1. Non-viral Gene Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. RNA-based Therapies
    • 4.5.1. RNA-based Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Messenger RNA (mRNA)
      • 4.5.2.1. Messenger RNA (mRNA) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Small Interfering RNA (siRNA)
      • 4.5.3.1. Small Interfering RNA (siRNA) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Antisense Oligonucleotides (ASO)
      • 4.5.4.1. Antisense Oligonucleotides (ASO) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Nucleic Acid Therapeutics Contract Manufacturing Market: Service Estimates & Trend Analysis

  • 5.1. Nucleic Acid Therapeutics Contract Manufacturing Market, By Service: Segment Dashboard
  • 5.2. Nucleic Acid Therapeutics Contract Manufacturing Market, By Service: Movement Analysis
  • 5.3. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
  • 5.4. Process Development and Optimization
    • 5.4.1. Process Development and Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. GMP Manufacturing
    • 5.5.1. GMP Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Analytical and Quality Control Service
    • 5.6.1. Analytical and Quality Control Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Fill-Finish Contract Manufacturing
    • 5.7.1. Fill-Finish Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Regulatory Support
    • 5.8.1. Regulatory Support Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Nucleic Acid Therapeutics Contract Manufacturing Market: Application Estimates & Trend Analysis

  • 6.1. Nucleic Acid Therapeutics Contract Manufacturing Market, By Application: Segment Dashboard
  • 6.2. Nucleic Acid Therapeutics Contract Manufacturing Market, By Application: Movement Analysis
  • 6.3. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates & Forecasts, By Application, 2021 - 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Rare Diseases
    • 6.5.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Genetic Disorders
    • 6.6.1. Genetic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Infectious Diseases
    • 6.7.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Nucleic Acid Therapeutics Contract Manufacturing Market: End Use Estimates & Trend Analysis

  • 7.1. Nucleic Acid Therapeutics Contract Manufacturing Market, By End Use: Segment Dashboard
  • 7.2. Nucleic Acid Therapeutics Contract Manufacturing Market, By End Use: Movement Analysis
  • 7.3. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 7.4. Large Biopharmaceutical Companies
    • 7.4.1. Large Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Medium Biopharmaceutical Companies
    • 7.5.1. Medium Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Small Biopharmaceutical Companies
    • 7.6.1. Small Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Others
    • 7.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Nucleic Acid Therapeutics Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Dashboard
  • 8.2. Regional Market Share Analysis, 2024 & 2033
  • 8.3. North America
    • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.2. U.S
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.3. Canada
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.4. Mexico
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4. Europe
    • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. UK
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Germany
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. France
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.5. Italy
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.6. Spain
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.7. Denmark
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.8. Sweden
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Competitive Scenario
      • 8.4.8.3. Regulatory Framework
      • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.9. Norway
      • 8.4.9.1. Key Country Dynamics
      • 8.4.9.2. Competitive Scenario
      • 8.4.9.3. Regulatory Framework
      • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. Japan
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. China
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. India
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Australia
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. South Korea
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Brazil
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. MEA
    • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. South Africa
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.4. Saudi Arabia
      • 8.7.4.1. Key Country Dynamics
      • 8.7.4.2. Competitive Scenario
      • 8.7.4.3. Regulatory Framework
      • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.5. Kuwait
      • 8.7.5.1. Key Country Dynamics
      • 8.7.5.2. Competitive Scenario
      • 8.7.5.3. Regulatory Framework
      • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.6. Qatar
      • 8.7.6.1. Key Country Dynamics
      • 8.7.6.2. Competitive Scenario
      • 8.7.6.3. Regulatory Framework
      • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.7. Oman
      • 8.7.7.1. Key Country Dynamics
      • 8.7.7.2. Competitive Scenario
      • 8.7.7.3. Regulatory Framework
      • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Key Participant Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
  • 9.3. Company Profiles
    • 9.3.1. Lonza Group
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Thermo Fisher Scientific
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Catalent Inc.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. WuXi AppTec
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. AGC Biologics
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Agilent Technologies
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Ajinomoto Bio-Pharma Services
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. BioSpring GmbH
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Bachem Holding AG
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. CordenPharma International GmbH
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Danaher Corporation
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Service Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. Eurofins Scientific
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Financial Performance
      • 9.3.12.3. Service Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. Avecia (Nitto Denko / Avecia)
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Financial Performance
      • 9.3.13.3. Service Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. BioCina Pty Ltd.
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Financial Performance
      • 9.3.14.3. Service Benchmarking
      • 9.3.14.4. Strategic Initiatives
    • 9.3.15. Kaneka Corporation
      • 9.3.15.1. Company Overview
      • 9.3.15.2. Financial Performance
      • 9.3.15.3. Service Benchmarking
      • 9.3.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 4 Global Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 5 Global Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 6 Global Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 8 North America Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 9 North America Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 10 North America Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 11 North America Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 12 U.S. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 13 U.S. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 14 U.S. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 15 U.S. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 16 Canada Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 17 Canada Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 18 Canada Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 19 Canada Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 20 Mexico Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 21 Mexico Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 22 Mexico Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 23 Mexico Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 24 Europe Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 25 Europe Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 26 Europe Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 27 Europe Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 28 Europe Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 29 UK Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 30 UK Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 31 UK Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 32 UK Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 33 Germany Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 34 Germany Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 35 Germany Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 36 Germany Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 37 France Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 38 France Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 39 France Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 40 France Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 41 Italy Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 42 Italy Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 43 Italy Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 44 Italy Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 45 Spain Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 46 Spain Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 47 Spain Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 48 Spain Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 49 Denmark Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 50 Denmark Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 51 Denmark Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 52 Denmark Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 53 Sweden Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 54 Sweden Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 55 Sweden Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 56 Sweden Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 57 Norway Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 58 Norway Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 59 Norway Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 60 Norway Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 66 Japan Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 67 Japan Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 68 Japan Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 69 Japan Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 70 China Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 71 China Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 72 China Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 73 China Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 74 India Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 75 India Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 76 India Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 77 India Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 78 Australia Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 79 Australia Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 80 Australia Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 81 Australia Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 82 Thailand Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 83 Thailand Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 84 Thailand Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 85 Thailand Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 86 South Korea Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 87 South Korea Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 88 South Korea Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 89 South Korea Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 90 Latin America Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 91 Latin America Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 92 Latin America Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 93 Latin America Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 94 Latin America Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 95 Brazil Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 96 Brazil Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 97 Brazil Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 98 Brazil Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 99 Argentina Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 100 Argentina Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 101 Argentina Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 102 Argentina Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 103 Middle East & Africa Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 108 South Africa Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 109 South Africa Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 110 South Africa Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 111 South Africa Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 116 UAE Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 117 UAE Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 118 UAE Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 119 UAE Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 120 Kuwait Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 122 Kuwait Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 123 Kuwait Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 124 Oman Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 125 Oman Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 126 Oman Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 127 Oman Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 128 Qatar Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
  • Table 129 Qatar Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 130 Qatar Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 131 Qatar Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 Nucleic Acid Therapeutics Contract Manufacturing Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Nucleic Acid Therapeutics Contract Manufacturing Market: Type outlook and key takeaways
  • Fig. 20 Nucleic Acid Therapeutics Contract Manufacturing Market: Type movement analysis
  • Fig. 21 Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Plasmid DNA (pDNA) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Viral Vectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Non-viral Gene Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 RNA-based Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Messenger RNA (mRNA) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Small Interfering RNA (siRNA) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Antisense Oligonucleotides (ASO) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Other Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Nucleic Acid Therapeutics Contract Manufacturing Market: Service outlook and key takeaways
  • Fig. 32 Nucleic Acid Therapeutics Contract Manufacturing Market: Service movement analysis
  • Fig. 33 Process Development and Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 GMP Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Analytical and Quality Control Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Fill-Finish Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Regulatory Support Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Nucleic Acid Therapeutics Contract Manufacturing Market: Application Outlook And Key Takeaways
  • Fig. 40 Nucleic Acid Therapeutics Contract Manufacturing Market: Application Movement Analysis
  • Fig. 41 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Genetic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Nucleic Acid Therapeutics Contract Manufacturing Market: End Use Outlook And Key Takeaways
  • Fig. 47 Nucleic Acid Therapeutics Contract Manufacturing Market: End Use Movement Analysis
  • Fig. 48 Large Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Medium Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Small Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Regional Marketplace: Key Takeaways
  • Fig. 53 North America Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 U.S. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Canada Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Mexico Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Europe Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 UK Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Germany Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 France Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Italy Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Spain Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Denmark Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Sweden Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Norway Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Asia Pacific Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Japan Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 China Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 India Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Australia Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Thailand Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 South Korea Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Latin America Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Brazil Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Argentina Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 95 MEA Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 South Africa Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 UAE Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 Saudi Arabia Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Kuwait Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 Qatar Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Oman Nucleic Acid Therapeutics Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 108 Key country dynamics
  • Fig. 109 Key company categorization
  • Fig. 110 Service heat map analysis
  • Fig. 111 Strategic framework